SG11201810976TA - Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof - Google Patents
Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereofInfo
- Publication number
- SG11201810976TA SG11201810976TA SG11201810976TA SG11201810976TA SG11201810976TA SG 11201810976T A SG11201810976T A SG 11201810976TA SG 11201810976T A SG11201810976T A SG 11201810976TA SG 11201810976T A SG11201810976T A SG 11201810976TA SG 11201810976T A SG11201810976T A SG 11201810976TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pyrimidin
- acrylamide
- dimethylamino
- ethoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351749P | 2016-06-17 | 2016-06-17 | |
| PCT/US2017/037872 WO2017218892A1 (en) | 2016-06-17 | 2017-06-16 | Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810976TA true SG11201810976TA (en) | 2019-01-30 |
Family
ID=60664309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810976TA SG11201810976TA (en) | 2016-06-17 | 2017-06-16 | Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10844045B2 (es) |
| EP (1) | EP3471730B1 (es) |
| JP (1) | JP6928964B2 (es) |
| KR (1) | KR20190018494A (es) |
| CN (1) | CN109937043A (es) |
| AU (1) | AU2017285448B2 (es) |
| BR (1) | BR112018075823A2 (es) |
| CA (1) | CA3027732A1 (es) |
| CO (1) | CO2018013416A2 (es) |
| EA (1) | EA201892661A1 (es) |
| IL (1) | IL263619A (es) |
| MX (1) | MX2018015508A (es) |
| PH (1) | PH12018502668A1 (es) |
| SG (1) | SG11201810976TA (es) |
| TW (1) | TW201800404A (es) |
| WO (1) | WO2017218892A1 (es) |
| ZA (1) | ZA201808234B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3638241B1 (en) | 2017-06-16 | 2022-05-25 | Beta Pharma, Inc. | Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof |
| CN110898026A (zh) * | 2019-12-11 | 2020-03-24 | 倍而达药业（苏州）有限公司 | 包含bpi-7711的药用组合物及其制备方法 |
| CN111100117B (zh) * | 2019-12-18 | 2021-02-19 | 上海倍而达药业有限公司 | 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2900230T3 (es) | 2011-07-27 | 2022-03-16 | Astrazeneca Ab | Compuestos de 2-(2,4,5-anilino sustituido)pirimidina |
| DE102011115849B3 (de) | 2011-10-13 | 2012-05-10 | Thomas Magnete Gmbh | Vorrichtung zum Dosieren und Zerstäuben von Flüssigkeiten mit vorgespanntem Dämpfer |
| US10227342B2 (en) * | 2014-06-19 | 2019-03-12 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CN105315285B (zh) | 2014-07-25 | 2017-12-08 | 上海海雁医药科技有限公司 | 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途 |
| WO2016029839A1 (zh) | 2014-08-25 | 2016-03-03 | 四川海思科制药有限公司 | 一种（取代的苯基）（取代的嘧啶）胺基衍生物及其制备方法和药物用途 |
| JP6456086B2 (ja) * | 2014-09-25 | 2019-01-23 | キヤノン株式会社 | 投影型画像表示装置及びその制御方法並びにプロジェクタ及びその制御方法 |
| CN111170998B (zh) * | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| MY183474A (en) | 2014-12-10 | 2021-02-19 | Oji Holdings Corp | Absorbent article |
| CN112375067B (zh) | 2014-12-11 | 2024-03-15 | 贝达医药公司 | 取代的2-苯胺基嘧啶衍生物及其作为表皮生长因子受体调节剂 |
| CN104961731A (zh) | 2015-02-05 | 2015-10-07 | 苏州晶云药物科技有限公司 | 一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法 |
| CN104910049B (zh) | 2015-06-16 | 2016-06-29 | 苏州明锐医药科技有限公司 | Azd9291中间体及其制备方法 |
| EP3454860A4 (en) | 2016-05-11 | 2020-01-15 | Beta Pharma, Inc. | 2-ANILINOPYRIMIDINE DERIVATIVES AS THERAPEUTIC ACTIVE SUBSTANCES FOR THE TREATMENT OF BRAIN CANCER |
-
2017
- 2017-06-16 EP EP17814169.3A patent/EP3471730B1/en active Active
- 2017-06-16 KR KR1020197001174A patent/KR20190018494A/ko not_active Application Discontinuation
- 2017-06-16 EA EA201892661A patent/EA201892661A1/ru unknown
- 2017-06-16 BR BR112018075823-0A patent/BR112018075823A2/pt not_active Application Discontinuation
- 2017-06-16 US US16/310,239 patent/US10844045B2/en active Active
- 2017-06-16 MX MX2018015508A patent/MX2018015508A/es unknown
- 2017-06-16 TW TW106120264A patent/TW201800404A/zh unknown
- 2017-06-16 AU AU2017285448A patent/AU2017285448B2/en active Active
- 2017-06-16 CA CA3027732A patent/CA3027732A1/en not_active Abandoned
- 2017-06-16 SG SG11201810976TA patent/SG11201810976TA/en unknown
- 2017-06-16 WO PCT/US2017/037872 patent/WO2017218892A1/en unknown
- 2017-06-16 CN CN201780050034.3A patent/CN109937043A/zh active Pending
- 2017-06-16 JP JP2018566304A patent/JP6928964B2/ja active Active
-
2018
- 2018-12-06 ZA ZA201808234A patent/ZA201808234B/en unknown
- 2018-12-10 IL IL263619A patent/IL263619A/en unknown
- 2018-12-12 CO CONC2018/0013416A patent/CO2018013416A2/es unknown
- 2018-12-17 PH PH12018502668A patent/PH12018502668A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018015508A (es) | 2019-04-11 |
| EP3471730A4 (en) | 2019-11-27 |
| CA3027732A1 (en) | 2017-12-21 |
| WO2017218892A1 (en) | 2017-12-21 |
| ZA201808234B (en) | 2019-11-27 |
| AU2017285448A1 (en) | 2019-01-03 |
| US20190233399A1 (en) | 2019-08-01 |
| EP3471730B1 (en) | 2021-10-20 |
| PH12018502668A1 (en) | 2019-10-07 |
| IL263619A (en) | 2019-01-31 |
| US10844045B2 (en) | 2020-11-24 |
| BR112018075823A2 (pt) | 2019-03-26 |
| KR20190018494A (ko) | 2019-02-22 |
| EA201892661A1 (ru) | 2019-07-31 |
| JP2019518062A (ja) | 2019-06-27 |
| CO2018013416A2 (es) | 2019-01-18 |
| CN109937043A (zh) | 2019-06-25 |
| AU2017285448B2 (en) | 2021-02-04 |
| TW201800404A (zh) | 2018-01-01 |
| EP3471730A1 (en) | 2019-04-24 |
| JP6928964B2 (ja) | 2021-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201809342YA (en) | Pyrimidine compounds as jak kinase inhibitors | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201908740VA (en) | Sustained release delivery systems comprising traceless linkers | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201408067YA (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903326RA (en) | Liposomal formulation for use in the treatment of cancer | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases |